Executive record

Marc H. Hedrick, M.D.

Director at PLUS THERAPEUTICS, INC.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:marc-h-hedrick-m-dVersion: public-0As of: 2026-09-29

Not yet claimed10 published Claims4 sources
  • Director

Key Claims

Biography

Dr. Hedrick joined Plus Therapeutics in October 2002 as Chief Scientific Officer, became President in May 2004, and CEO in April 2014. He previously served as President and CEO of StemSource and Chief Scientific Officer and Medical Director of Macropore Biosurgery. He was an Associate Professor of Surgery and Pediatrics at UCLA and is a trained general, vascular and plastic surgeon.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: President and Chief Executive Officer · Organization not publishedPSTV DEF 14A executive officers
  2. Dates not publishedExecutive title: Chief Executive Officer and President · Organization not publishedPSTV DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. PSTV DEF 14A director slate

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Plus Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Executive Officer and President · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. PSTV DEF 14A executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Plus Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. Open source

    sec proxy · Source published: Mar 31, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at PLUS THERAPEUTICS, INC. · Claim reviewed: May 16, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of PLUS THERAPEUTICS, INC. · Claim reviewed: May 16, 2026